Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TOCA
Previous Symbol
CUSIPN/A
Phone858-412-8400
Debt
Debt-to-Equity Ratio0.55
Current Ratio5.83
Quick Ratio5.83
Price-To-Earnings
Trailing P/E Ratio-4.78
Forward P/E Ratio-5.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales6,339.11
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.59 per share
Price / Book3.54
Profitability
EPS (Most Recent Fiscal Year)($2.66)
Net Income$-38,920,000.00
Net Margins-222.81%
Return on Equity-71.61%
Return on Assets-46.13%
Miscellaneous
Employees67
Outstanding Shares19,950,000
Market Cap$257.80 million
OptionableOptionable
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.22. The company had revenue of $18.01 million for the quarter, compared to the consensus estimate of $2.01 million. Tocagen had a negative net margin of 222.81% and a negative return on equity of 71.61%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
5 brokers have issued 12 month price targets for Tocagen's stock. Their predictions range from $15.00 to $30.00. On average, they expect Tocagen's stock price to reach $22.80 in the next year. This suggests a possible upside of 79.4% from the stock's current price. View Analyst Price Targets for Tocagen.
What is the consensus analysts' recommendation for Tocagen?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tocagen.
Has Tocagen been receiving favorable news coverage?
News headlines about TOCA stock have trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tocagen earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include Amphastar Pharmaceuticals (AMPH), Apellis Pharmaceuticals (APLS), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX), Dicerna Pharmaceuticals (DRNA), ImmunoGen (IMGN), Y-mAbs Therapeutics (YMAB) and Lexicon Pharmaceuticals (LXRX).
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 56)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 67)
- Mr. Mark G. Foletta CPA, Exec. VP & CFO (Age 57)
- Dr. Harry E. Gruber, Co-Founder, Pres of Science & Innovation and Director (Age 65)
- Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 70)
When did Tocagen IPO?
(TOCA) raised $80 million in an initial public offering on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.
Who are Tocagen's major shareholders?
Tocagen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.08%), Vanguard Group Inc. (3.95%), JPMorgan Chase & Co. (1.85%), JPMorgan Chase & Co. (1.85%), FMR LLC (1.77%) and Bank of New York Mellon Corp (0.26%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.
Which institutional investors are selling Tocagen stock?
TOCA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Russell Investments Group Ltd., JPMorgan Chase & Co. and JPMorgan Chase & Co.. View Insider Buying and Selling for Tocagen.
Which institutional investors are buying Tocagen stock?
TOCA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Dimensional Fund Advisors LP, Citadel Advisors LLC, Beaumont Financial Partners LLC, TIAA CREF Investment Management LLC, Alps Advisors Inc. and Bank of New York Mellon Corp. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $12.71.
How big of a company is Tocagen?
Tocagen has a market capitalization of $257.80 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.
What is Tocagen's official website?
How can I contact Tocagen?
Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (NASDAQ TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
